$WAT

Waters Corporation (WAT), a $40.7B life sciences and diagnostics company, reported Q2 2026 adjusted EPS of $3.05 and revenue of $1.65B, exceeding expectations. The stock has risen 43% over 52 weeks, outperforming the S&P 500. Analysts expect 10.9% EPS growth for 2026, with a consensus 'Moderate Buy' rating and a mean price target of $438.43.

Waters Corp. (WAT) rose 1.8% to a 52-week high of $426.22 after Piper Sandler upgraded it to Overweight with a $480 price target, up from $400, citing expected demand recovery.

Piper Sandler upgraded Waters Corporation (WAT) to Overweight, raising its price target to $480 from $400. The company's stock is currently trading at $423.22, slightly above its GF Value™ of $411.65, indicating a 2.8% overvaluation. Waters Corporation has a GF Score™ of 95/100, reflecting strong growth and momentum but moderate financial strength. Insider activity shows recent selling of $1,442,930 worth of shares.

Analysts made several rating changes: Truist initiated DigitalOcean as buy, citing AI growth; Citi downgraded Abercrombie & Fitch to neutral; Baird upgraded Synopsys to outperform. Other notable moves include upgrades for SQM, Synopsys, Extra Space Storage, and downgrades for Celsius, Regions, and Novo Nordisk. Bank of America reiterated Nvidia as buy, highlighting strong AI growth.

Analysts updated recommendations for multiple companies. Block (SQ) was upgraded to outperform with a raised price target of $98. Celsius (CELH) was downgraded to hold with a target of $35. CrowdStrike (CRWD) and Nvidia (NVDA) had targets raised to $235 and $400, respectively. Other companies saw changes in ratings or targets.

RBC Capital Markets reduced its 2027 operating-margin expansion forecast for Waters Corp. to 200 basis points, citing lower margins from Becton Dickinson assets. Despite this, RBC maintained a $475 price target and outperform rating, noting 3% higher EPS estimates than consensus. The firm cited mixed demand trends, with strong microbiology but weaker research-related sales. Waters' stock last traded at $407.93.

Waters Corporation (WAT) is in focus after a leadership change, with shares up 10.75% in 1 month and 19.96% in 3 months. The company's valuation is debated, with some analysts suggesting it is undervalued based on long-term cash flow potential, while others point to a rich sales multiple. Recurring revenues are accelerating, but risks include integration challenges and weaker demand in certain sectors.

WATERS CORP /DE/ (WAT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On August 17, 2026, Robert L. Carpio III notified Waters Corporation (the “Company”) of his decision to resign from his

Waters (WAT) reported Q2 2026 revenue of $1.645 billion, above the top of guidance, with 9% organic growth and adjusted EPS of $3.05. Full-year 2026 guidance was raised to 7% to 9% organic revenue growth and adjusted EPS of $14.45 to $14.65. Management cited cost actions, FX headwinds, China DRG headwinds, and progress in acquired biosciences and diagnostics.

Waters (NYSE:WAT) reported Q2 updates from its earnings call. Materials Science Division revenue rose to $87M. Biosciences and Diagnostic Solutions acquired from BD generated $817M revenue. Waters raised FY organic constant-currency growth outlook to 7% to 9%, projecting FY reported revenue of $3.370B to $3.431B and adjusted EPS of $14.45 to $14.65.